In a US retrospective study of data on veterans with compensated cirrhosis, more than half progressed to complications after approximately 5 years.

Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January 2025, Atea is initiating a global Phase 3 program and expects patient ...

The UK Health Security Agency (UKHSA) has announced the launch of a whole genome sequencing service to tackle hepatitis C virus (HCV). The service is aimed at monitoring drug resi ...

A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.

The UK Health Security Agency (UKHSA) has recently launched a genomic surveillance programme to monitor the HCV and its ...

Latest data show continued progress towards elimination of hepatitis C as a public health threat in England The UK Health ...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q4 2024 Earnings Call Transcript March 6, 2025 Atea Pharmaceuticals, Inc. misses on ...

Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV)Patient Enrollment in Global Phase 3 HCV ...

Results to-date demonstrate the potency of our potential best-in-class regimen with a short ... for treatment of hepatitis C virus (HCV), met its primary endpoints. Atea plans to conduct two ...

Upon arriving at our hospital, the patient’s body temperature was recorded to be 37.1°C, with no jaundice or hepatosplenomegaly observed. The patient appeared healthy and had no family history of ...

Giacomo Germani, M.D.; Prodromos Hytiroglou, M.D.; Anastasia Fotiadu, M.D.; Andrew K. Burroughs, F.Med.Sci.; Amar P. Dhillon, M.D.